Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart rehab may tweak cell death pathways — a study investigates

NCT ID NCT07722637

Knowledge-focused Sponsor: TC Erciyes University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 30, 2026 · Updated 5 times

Summary

This study examines whether a structured cardiac rehabilitation program — including exercise, education, and lifestyle changes — can influence ferroptosis, a form of regulated cell death, in people with coronary artery disease. Researchers will compare gene expression and blood markers related to ferroptosis among three groups: patients who undergo rehab, those who decline it, and healthy volunteers. The goal is to uncover whether rehab's benefits extend to the molecular level, potentially opening new avenues for heart disease management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a supervised cardiac rehabilitation program including exercise, education, and lifestyle changes
What this could lead to
If successful, this could reveal a new biological pathway through which cardiac rehabilitation benefits the heart, potentially leading to more targeted therapies.
What could go wrong
This is an early-stage observational study with a small sample size. It measures biomarkers, not clinical outcomes, so any link to real-world benefits remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients With Coronary Artery Disease (CAD): * Age between 18 and 75 years. * Diagnosis of coronary artery disease within the previous 3 months. * Eligible to participate in a cardiac rehabilitation program or voluntarily decline participation in the cardiac rehabilitation program. * Peak exercise capacity of ≥5 metabolic equivalents (METs). * Able to undergo cardiopulmonary exercise testing (CPET). * Able to understand the study procedures and provide written informed consent. Healthy Controls: * Age between 18 and 75 years. * No history of coronary artery disease or other cardiovascular diseases. * No history of chronic systemic diseases, including diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, inflammatory or autoimmune diseases, or malignancy. * Not receiving regular medication. * Able to provide written informed consent. Exclusion Criteria: Patients With Coronary Artery Disease (CAD): * Decompensated heart failure. * Unstable angina pectoris. * Uncontrolled or complex ventricular arrhythmias. * Severe pulmonary hypertension. * Neurological, orthopedic, or musculoskeletal disorders limiting exercise performance. * Absolute contraindications to cardiopulmonary exercise testing or cardiac rehabilitation according to current clinical guidelines. * Chronic kidney failure or chronic liver disease. * Active infection. * Active inflammatory or autoimmune disease. * Active malignancy or history of malignancy. * Pregnancy. * Cognitive or psychiatric disorders that would interfere with study participation or protocol compliance. Healthy Controls: * History of coronary artery disease or other cardiovascular diseases. * History of chronic systemic diseases, including diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, inflammatory or autoimmune diseases, or malignancy. * Regular medication use within the previous 6 months. * Active infection. * Pregnancy. * Age younger than 18 years or older than 75 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac rehab are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac rehab Coronary artery disease (CAD) Ferroptosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erciyes University Faculty of Medicine

    RECRUITING

    Kayseri, Kayseri, 38039, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.